Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
Saved in:
| Published in: | Rheumatology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868552386391310336 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Rheumatology and Therapy |
| description | |
| discipline_display | Rheumatology |
| discipline_facet | Rheumatology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:58290 |
| institution | FRELIP |
| journal_source_facet | Rheumatology and Therapy |
| last_indexed | 2026-06-20T21:19:56.163Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) Rheumatology General Rheumatology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Rheumatology General Rheumatology |
| subject_facet | Rheumatology General Rheumatology |
| title | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_alt | Olokizumab mejora los resultados informados por el paciente en pacientes con artritis reumatoide activa hasta 106 semanas (resultados de la extensión abierta de ensayos clínicos aleatorizados de fase III) L'olokizumab améliore les résultats rapportés par les patients atteints de polyarthrite rhumatoïde active jusqu'à 106 semaines (résultats de l'extension en ouvert d'essais cliniques randomisés de phase III) Olokizumabe Melhora os Desfechos Relatados pelo Paciente em Pacientes com Artrite Reumatoide Ativa até 106 Semanas (Resultados da Extensão Aberta de Ensaios Clínicos Randomizados de Fase III) |
| title_auth | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_es_txt | Olokizumab mejora los resultados informados por el paciente en pacientes con artritis reumatoide activa hasta 106 semanas (resultados de la extensión abierta de ensayos clínicos aleatorizados de fase III) |
| title_fr_txt | L'olokizumab améliore les résultats rapportés par les patients atteints de polyarthrite rhumatoïde active jusqu'à 106 semaines (résultats de l'extension en ouvert d'essais cliniques randomisés de phase III) |
| title_full | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_fullStr | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_full_unstemmed | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_pt_txt | Olokizumabe Melhora os Desfechos Relatados pelo Paciente em Pacientes com Artrite Reumatoide Ativa até 106 Semanas (Resultados da Extensão Aberta de Ensaios Clínicos Randomizados de Fase III) |
| title_short | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_sort | olokizumab improves patient-reported outcomes in patients with active rheumatoid arthritis up to 106 weeks (results from the open-label extension of phase iii randomized clinical trials) |
| topic | Rheumatology General Rheumatology |
| url | https://link.springer.com/article/10.1007/s40744-026-00852-3 |